Index»
against
»
cancer
»
esophageal
»
may
»
protect
»
statins
»
Statins may protect against esophageal cancer
Statin use is associated with protection from esophagus cancer according to a new meta-analysis of existing clinical studies exploring the cancer prevention effects of statins presented by a Mayo Clinic researcher, Dr. Siddharth Singh, at the American College of Gastroenterology 77th Annual Scientific Meeting in Las Vegas, NV.
Dr. Singh and his Mayo colleagues conducted a systematic review of eleven studies reporting 8,613 cases of esophageal cancer from studies including almost 1 million patients. Incidence of esophageal cancer is increasing in the United States, especially esophageal adenocarcinoma in patients with Barretts esophagus.
"The meta-analysis of these studies showed a significant 30 percent reduction in esophageal cancer incidence with statins use," said Dr. Singh.
When looking more closely at the seven highest-quality observational studies among the eleven, researchers continued to find a significant chemo-protective effect with statin use. An analysis of a subset of patients with Barretts esophagus, a pre-malignant condition associated with chronic acid lux, revealed that, in this higher risk population, statin use was associated with a significant 41 percent decrease in the risk of adenocarcinoma of the esophagus.
Statins may protect against esophageal cancer
Saturday, May 10, 2014
Statin use is associated with protection from esophagus cancer according to a new meta-analysis of existing clinical studies exploring the cancer prevention effects of statins presented by a Mayo Clinic researcher, Dr. Siddharth Singh, at the American College of Gastroenterology 77th Annual Scientific Meeting in Las Vegas, NV.
Dr. Singh and his Mayo colleagues conducted a systematic review of eleven studies reporting 8,613 cases of esophageal cancer from studies including almost 1 million patients. Incidence of esophageal cancer is increasing in the United States, especially esophageal adenocarcinoma in patients with Barretts esophagus.
"The meta-analysis of these studies showed a significant 30 percent reduction in esophageal cancer incidence with statins use," said Dr. Singh.
When looking more closely at the seven highest-quality observational studies among the eleven, researchers continued to find a significant chemo-protective effect with statin use. An analysis of a subset of patients with Barretts esophagus, a pre-malignant condition associated with chronic acid lux, revealed that, in this higher risk population, statin use was associated with a significant 41 percent decrease in the risk of adenocarcinoma of the esophagus.
Subscribe to:
Post Comments (Atom)
.jpg)
No comments:
Post a Comment